Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B)
- James Chih Hsin Yang
- , Yuichiro Ohe
- , Chao Hua Chiu
- , Xiaoling Ou
- , Mireille Cantarini
- , Pasi A. Jänne
- , Ryan J. Hartmaier
- , Myung Ju Ahn
- National Taiwan University
- National Cancer Center Japan
- Veterans General Hospital-Taipei
- AstraZeneca
- Dana-Farber Cancer Institute
Research output: Contribution to journal › Article › peer-review
19
Link opens in a new tab
Scopus
citations